BioStock: DanCann's CEO on his expectations for the coming months

Danish biopharmaceutical company DanCann Pharma has had an eventful summer. Not only did they announce that the development of the company’s first production facilities exceeded the expectations, but also that the REBORN trial can be accelerated. In addition to this DanCann Pharma carried out a directed issue of shares of circa 6.375 million DKK and warrants in late July. BioStock reached out to founder and CEO, Jeppe Krog Rasmussen, to learn more about the company’s achievements so far this year and find out what his expectations are for the coming months. 

Read the full interview with Jeppe Krog Rasmussen at biostock.se:

https://www.biostock.se/en/dancanns-ceo-on-his-expectations-for-the-coming-months/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/